Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab for gastrointestinal tumors
ChiCTR2400084387Phase 2Not yet recruiting
- Sponsor
- Dengzhou People's Hospital
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in esophageal cancer, gastric cancer (GC), colorectal cancer (CRC) and 3 more, sponsored by Dengzhou People's Hospital. Primary endpoints: Progression-free survival, Objective response rate and 1 more. Planned start May 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
esophageal cancergastric cancer (GC)colorectal cancer (CRC)biliary cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400084387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084387.